Showing results (101-110 of 112) with videos related to

Sort By:
Pageof 12
Human Vaccines & Immunotherapeutics|November 12, 2020
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trialShangying Hu, Xiaoqian Xu, Fengcai Zhu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|October 15, 2025
Relationship between age at diagnosis and recurrence characteristics in adult-onset recurrent respiratory papillomatosis: a nationwide multicenter study from ChinaQijian Zheng, Changchang Dun, Wenbin Lei, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 3, 2025
Characteristics of juvenile-onset recurrent respiratory papillomatosis in China, 2011-2021: A hospital-based nationwide studyChangchang Dun, Yutong Li, Wenbin Lei, et al.
BMC Medicine|December 22, 2020
Development and validation of an artificial intelligence system for grading colposcopic impressions and guiding biopsiesPeng Xue, Chao Tang, Qing Li, et al.
Preventive Medicine|December 13, 2021
Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancerNathalie Broutet, Jose Jeronimo, Somesh Kumar, et al.
International Journal of Cancer|December 13, 2024
The variations in the natural history of high-risk human papillomavirus infections in Chinese healthy women aged 27-45 years compared with 18-26 years: A prospective cohort studyQi Chen, Xingmei Yao, Jiali Quan, et al.
Asia-Pacific Journal of Clinical Oncology|September 14, 2022
Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18-25 years: A 10-year follow-up studyFanghui Zhao, Archana Jastorff, Ying Hong, et al.
Vaccine|August 25, 2022
Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021-March 2022Holly J Prudden, Sharon L Achilles, Celina Schocken, et al.
The Lancet Regional Health. Western Pacific|September 2, 2025
Long-term efficacy and immunopersistence of an <i>Escherichia coli</i>-produced HPV-16/18 bivalent vaccine: an observational extension study following a randomised, double-blind Phase III clinical trial cohortFanghui Zhao, Qi Chen, Chao Zhao, et al.
Cancer Letters|January 25, 2026
Changing Landscape in Stage, Treatment and Survival of Gastric Cancer in China 1998-2022: Insights of 40,158 patients from the National Gastric Cancer CohortLulu Zhao, Zhihao Chen, Fan Zhang, et al.
Pageof 12